E&T

Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition

Retrieved on: 
Wednesday, December 8, 2021
Heart failure, ICI, Dell Technologies, Quality of life, Patient, Industry, Partnership, CHF, E&T, TEL, Engineering & Technology, Cerebral edema, Clothing, Association of British HealthTech Industries, FDA, Conditional sentence, Solution, AI, First Place, Pharmaceutical industry, Medical device

TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Donisi Health (Donisi) prevailed in this year's ICI Innovation Competition – the premier international conference for innovations in cardiovascular intervention. Competing against startups from all over the world in front of a panel of twenty industry expert judges, Donisi took home First Place honors and a $200,000 award for their innovative solution to enable in-home monitoring for key health bio-markers for patients with Congestive Heart Failure (CHF) and other chronic diseases.

Key Points: 
  • Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.
  • Based upon FDA-cleared technology and backed by 11 granted patents, Donisi's AI-based system detects and analyzes multiple health bio-indicators simultaneously - without the need to remove clothing or connect the patient to wires or patches - delivering clinically meaningful insights and notifications of changes in key health indicators.
  • "We are honored to be recognized by this prestigious institution, and are grateful to the ICI team for highlighting our breakthrough technology's potential to meaningfully improve cardiovascular health," said Donisi's CEO Yair Brosh.
  • "This doesn't need to be the case," said Donisi's new Chief Medical Officer, Dr. Shaddy Hassan.

Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition

Retrieved on: 
Wednesday, December 8, 2021
Heart failure, ICI, Dell Technologies, Quality of life, Patient, Industry, Partnership, CHF, E&T, TEL, Engineering & Technology, Cerebral edema, Clothing, Association of British HealthTech Industries, FDA, Conditional sentence, Solution, AI, First Place, Pharmaceutical industry, Medical device

Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.

Key Points: 
  • Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.
  • Based upon FDA-cleared technology and backed by 11 granted patents, Donisi's AI-based system detects and analyzes multiple health bio-indicators simultaneously - without the need to remove clothing or connect the patient to wires or patches - delivering clinically meaningful insights and notifications of changes in key health indicators.
  • "We are honored to be recognized by this prestigious institution, and are grateful to the ICI team for highlighting our breakthrough technology's potential to meaningfully improve cardiovascular health," said Donisi's CEO Yair Brosh.
  • "This doesn't need to be the case," said Donisi's new Chief Medical Officer, Dr. Shaddy Hassan.

Donisi Health Named 2021's "Future Unicorn" by E&T Magazine

Retrieved on: 
Monday, December 6, 2021
Patient, Health status of Asian Americans, Algorithm, Heart, CEO, AI, Cerebral edema, Medtech, Unicorn, Engineering & Technology, Artificial intelligence, CHF, TEL, FDA, IET, Heart failure, E&T, Clothing, Medical device

TEL AVIV, Israel, Dec. 6, 2021 /PRNewswire/ -- E&T Magazine, the official publication of the Institution of Engineering and Technology (IET), presented its "Future Unicorn" award to Donisi Health (Donisi), a MedTech company enabling patients with Congestive Heart Failure (CHF) and other chronic diseases monitor their health status.  Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.

Key Points: 
  • TEL AVIV, Israel, Dec. 6, 2021 /PRNewswire/ --E&T Magazine, the official publication of the Institution of Engineering and Technology (IET), presented its "Future Unicorn" award to Donisi Health (Donisi), a MedTech company enabling patients with Congestive Heart Failure (CHF) and other chronic diseases monitor their health status.
  • Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.
  • Based upon FDA-cleared technology and backed by 11 granted patents,Donisi's AI-based system detects and analyzes multiple health bio-indicators simultaneously, delivering clinically meaningful insights and notifications of changes in key health indicators.
  • "We are honored to receive this prestigious award from E&T Magazine confirming Donisi is on the right path to bringing a disruptive solution to meaningfully impact patient health," said Donisi's CEO, Yair Brosh.

Donisi Health Named 2021's "Future Unicorn" by E&T Magazine

Retrieved on: 
Monday, December 6, 2021
Patient, Health status of Asian Americans, Algorithm, Heart, CEO, AI, Cerebral edema, Medtech, Unicorn, Engineering & Technology, Artificial intelligence, CHF, TEL, FDA, IET, Heart failure, E&T, Clothing, Medical device

TEL AVIV, Israel, Dec. 6, 2021 /PRNewswire/ --E&T Magazine, the official publication of the Institution of Engineering and Technology (IET), presented its "Future Unicorn" award to Donisi Health (Donisi), a MedTech company enabling patients with Congestive Heart Failure (CHF) and other chronic diseases monitor their health status.

Key Points: 
  • TEL AVIV, Israel, Dec. 6, 2021 /PRNewswire/ --E&T Magazine, the official publication of the Institution of Engineering and Technology (IET), presented its "Future Unicorn" award to Donisi Health (Donisi), a MedTech company enabling patients with Congestive Heart Failure (CHF) and other chronic diseases monitor their health status.
  • Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services.
  • Based upon FDA-cleared technology and backed by 11 granted patents,Donisi's AI-based system detects and analyzes multiple health bio-indicators simultaneously, delivering clinically meaningful insights and notifications of changes in key health indicators.
  • "We are honored to receive this prestigious award from E&T Magazine confirming Donisi is on the right path to bringing a disruptive solution to meaningfully impact patient health," said Donisi's CEO, Yair Brosh.